Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy

Aaron Tan 1, Maria V. Babak 2, Gopalakrishnan Venkatesan 2, Clarissa Lim 2, Karl-Norbert Klotz 3, Deron Raymond Herr 4, Siew Lee Cheong 5,*, Stephanie Federico 6, Giampiero Spalluto 6, Wei-Yi Ong 7, Yu Zong Chen 2, Jason Siau Ee Loo 8,*,* and Giorgia Pastorin 1,2,*

1 NUS Graduate School of Integrative Sciences and Engineering, National University of Singapore, Centre for Life Sciences, #05-01, 28 Medical Drive, Singapore 117456, Singapore; aarontan@u.nus.edu
2 Department of Pharmacy, National University of Singapore, Singapore 119260, Singapore; maria.babak@nus.edu.sg (M.V.B.); phagove@nus.edu.sg (G.V.); scifryc@nus.edu.sg (C.L.); csscyz@nus.edu.sg (Y.Z.C.)
3 Institut für Pharmakologie und Toxikologie, Universität Würzburg, 97078 Würzburg, Germany; klotz@toxi.uni-wuerzburg.de
4 Department of Pharmacology, National University of Singapore, Singapore 117600, Singapore; phcdrh@nus.edu.sg
5 Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, 126 Jalan Jalil Perkasa 19, Bukit Jalil, Kuala Lumpur 57000, Malaysia
6 Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, 34127 Trieste, Italy; sfederico@units.it (S.F.); spalluto@units.it (G.S.)
7 Department of Anatomy, National University of Singapore, Singapore 119260, Singapore; antongwy@nus.edu.sg
8 School of Pharmacy, Faculty of Health and Medical Sciences, Taylor’s University, 1, Jalan Taylors, Subang Jaya, Selangor 47500, Malaysia
* Correspondence: CheongSiewLee@imu.edu.my (S.L.C.); JasonSiauEe.Loo@taylors.edu.my (J.S.E.L.); phapg@nus.edu.sg (G.P.)

Academic Editor: Loredana Cappellacci
Received: 20 September 2019; Accepted: 8 October 2019; Published: 11 October 2019

Abstract: Human A3 adenosine receptor hA3AR has been implicated in gastrointestinal cancer, where its cellular expression has been found increased, thus suggesting its potential as a molecular target for novel anticancer compounds. Observation made in our previous work indicated the importance of the carbonyl group of amide in the indolylpyrimidylpiperazine (IPP) for its human A2A adenosine receptor (hA2AAR) subtype binding selectivity over the other AR subtypes. Taking this observation into account, we structurally modified an indolylpyrimidylpiperazine (IPP) scaffold, 1 (a non-selective adenosine receptors’ ligand) into a modified IPP (mIPP) scaffold by switching the position of the carbonyl group, resulting in the formation of both ketone and tertiary amine groups in the new scaffold. Results showed that such modification diminished the A2A activity and instead conferred hA3AR agonistic activity. Among the new mIPP derivatives (3–6), compound 4 showed potential as a hA3AR partial agonist, with an E_{max} of 30% and EC_{50} of 2.89 ± 0.55 µM. In the cytotoxicity assays, compound 4 also exhibited higher cytotoxicity against both colorectal and liver cancer cells as compared to normal cells. Overall, this new series of compounds provide a promising starting point for further development of potent and selective hA3AR partial agonists for the treatment of gastrointestinal cancers.

Keywords: gastrointestinal cancer; hA3AR; partial agonists; indolylpyrimidylpiperazines
1. Introduction

Gastrointestinal (GI)-related cancers are pathological conditions that account for at least 30% of cancer-related deaths worldwide [1]. Among them, liver cancer has shown an increasing incidence, which is projected to rise by 35% by 2030 [2]. Colorectal cancer is also becoming a predominant cancer worldwide, with 746,300 and 614,300 new cases reported in 2012 among men and women, respectively [3]; its incidence and death rates are projected to rise by 60% by 2030 [4]. This projection is indicative of colorectal cancer becoming the cancer with the highest incidence and the second most prevalent cause of cancer-related deaths by 2030.

The current chemotherapeutic options for colorectal cancers are limited. Nonetheless, a study conducted by Bar-Yehuda et al. showed that a human A\textsubscript{3} adenosine receptor (hA\textsubscript{3}AR)-selective agonist, CF101 (IB-MECA), was able to enhance the chemotherapeutic efficacy of 5-fluorouracil in a colon carcinoma murine model. Sakowicz-Burkiewicz et al. also observed that the treatment of HCT-116 human colorectal carcinoma cells with CF101 had resulted in an increase in apoptosis and necrosis of the cancer cells [5]. A phase II clinical trial on human colon carcinoma patients showed CF101 exhibiting disease stabilization potential in 35% of the patients [6]. In addition, CF101 also exhibited a myeloprotective effect in the murine model [7], suggesting improved tolerability and decreased side effects. From these studies, it emerges that the activation of the hA\textsubscript{3}AR clearly plays a crucial role in tumour progression: this receptor is overexpressed in several pathological conditions [8] such as colorectal cancer [9,10], breast cancer [10,11], brain cancer [12] and leukaemia [13]. Patients suffering from colorectal cancer were also reported to have a higher expression level of the hA\textsubscript{3}AR at the tumour site as compared to adjacent, remote, and healthy colon mucosa. Furthermore, the level of upregulation of hA\textsubscript{3}AR was found to be directly correlated to the disease severity [9], making it a representative biomarker for colorectal cancer.

Similarly, poor prognosis is associated with advanced stage liver cancer patients, where drugs such as doxorubicin and cisplatin do not exhibit improved survival rate (as observed in various phase III clinical trials) and are accompanied with significant toxicity [14]. Hence, many research groups are exploring new molecular targets for advanced stages of liver cancer. One current phase II clinical trial is investigating the use of CF102 (2-Cl-IB-MECA), a hA\textsubscript{3}AR-selective agonist, to improve the overall survival rate of advanced liver cancer patients while maintaining a low toxicity profile. Earlier phase I/II clinical trials on 18 advanced stage liver cancer patients showed that a patient who developed metastases prior to CF102 treatment had achieved a complete metastasis regression during the three-month treatment with CF102 [15]. The success of both CF101 and CF102 demonstrate the potential for selective hA\textsubscript{3}AR agonists.

In our previous work, we had developed a hA\textsubscript{2A}AR-selective ligand, 1. An observation based on such work indicated that a simple chemical modification in the scaffold of 1 was able to convert a selective hA\textsubscript{2A}AR ligand with K\textsubscript{i} hA\textsubscript{2A}AR = 8.71 µM and selectivity hA\textsubscript{2A}AR/hA\textsubscript{3}AR > 12 into a non-selective ligand, 2, with K\textsubscript{i} hA\textsubscript{2A}AR = 34.40 µM and K\textsubscript{i} hA\textsubscript{3}AR = 39.80 µM (Figure 1). In other words, the simple removal of the carbonyl group of amide in 1 had led to the loss of binding selectivity towards the hA\textsubscript{2A}AR [16].

In continuation to the previous studies, we aimed to investigate the effect of switching the position of the carbonyl group on indolylpyrimidylpiperazine (IPP) towards the activity at both A\textsubscript{2A} and A\textsubscript{3} receptors in our present work. Hence, we carried out structural modifications of IPP (1) by shifting the carbonyl group to the position adjacent to the indole ring as shown in the modified IPP (mIPP), 3, producing both a ketone group and a tertiary amine group in the new scaffold. It is postulated that such modification would eventually diminish the A\textsubscript{2A} activity while gaining activity at the A\textsubscript{3} receptor. Based on the mIPP scaffold, 3, we introduced different substituents on the 7th position of the indole ring, generating the series of compounds, 4–6 (shown in Figure 2).
2. Results and Discussion

2.1. Chemistry

Compound 3 was synthesized based upon the synthetic scheme (Scheme 1), in which indole was treated dropwise with chloroacetylchloride in the presence of pyridine for an hour at 60 °C in dioxane to give 2-chloro-1-(1H-indol-3-yl)ethanone (7), with a yield of 50% [17].

The same synthetic scheme could not be applied for the synthesis of compounds 4–6, as the substituted chloroacetylmidoles could not be produced using the same reaction condition as for the synthesis of compound 7.
Compounds 4 and 5 were synthesized based on the synthetic scheme (Scheme 2), where both 7-methoxyindole and 7-chloroindole were treated with chloroacetyl chloride in the presence of 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) under a pressurized reaction condition in dichloroethane (DCE) at 90 °C for a reaction period of 2–5 days to afford 2-chloro-1-(7-methoxy-1H-indol-3-yl)ethanone (9) and 2-chloro-1-(7-chloro-1H-indol-3-yl)ethanone (10) in 23% and 11% yield, respectively [18].

Compound 6 was obtained through the Vilsmeier-Haack acylation for synthesis of compound 12, 2-chloro-1-(7-nitro-1H-indol-3-yl)ethanone, as presented in Scheme 3. 2-Chloro-N,N-dimethylacetamide (11) was first synthesized from chloroacetyl chloride and dimethylamine hydrochloride salt in the presence of triethylamine (TEA) and was subsequently used in a Vilsmeier-Haack acylation.
of 7-nitroindole in the presence of phosphoryl oxychloride at room temperature for 18 h to give 2-chloro-1-(7-nitro-1H-indol-3-yl)ethenone (12) with a yield of 17% [19].

Scheme 3. Synthetic scheme for the synthesis of compound 6.

To minimize the formation of 2-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-4,6-dimethylpyrimidine, five equivalents of piperazine were reacted with one equivalent of 2-chloro-4,6-dimethylpyrimidine in a solvent mixture of tetrahydrofuran (THF) and water with a ratio of 1:4 at room temperature for 24 h in the presence of base to give 4,6-dimethyl-2-(piperazin-1-yl)pyrimidine (8) with a yield of 96% (Scheme 1) [20].

Compounds 3–6 were then obtained from reaction between compound 8 and their respective chloroacetylindoles 7, 9, 10 and 12 in the presence of sodium iodide and base under reflux for 24 h, with respective yields of 38%, 77%, 59% and 69% [21].

2.2. Biological Evaluation

2.2.1. Functional Activity Studies at hA2AAR and hA3AR

Functional activity of compounds 3–6 was determined using the transforming growth factor alpha (TGFα) shedding assay. This recently-developed assay utilizes an alkaline phosphatase-TGFα fusion protein reporter system to quantitatively evaluate specific GPCR-mediated G protein activation (shown in Figure 3) of test compounds [22].
is essentially inactive against the hA3AR. Similarly, compounds 5 and 6 are also weak hA3AR agonists, with respective EC50 values of 13.4 ± 2.96 μM and 33.2 ± 16.50 μM but have higher efficacy of 77% and 72%, respectively. On the other hand, compound 3 is essentially inactive against the hA3AR.

The TGFα shedding assay workflow results of compounds 3–6 on hA3AR (shown in Figure 4), summarized in Table 1, revealed that the compounds exhibited agonistic activity at the A3 receptor. Compound 4 is the most potent hA3AR agonist among the four compounds 3–6, with an EC50 of 2.89 ± 0.55 μM. It is also a partial hA3AR agonist, with an E_max of 31%, as compared to the efficacy of adenosine. Similarly, compounds 5 and 6 are also weak hA3AR agonists, with respective EC50 values of 13.4 ± 2.96 μM and 33.2 ± 16.50 μM but have higher efficacy of 77% and 72%, respectively. On the other hand, compound 3 is essentially inactive against the hA3AR.

![Figure 3. TGFα shedding assay workflow.](image)

![Figure 4. TGFα shedding assay results at the hA3AR for compounds 3–6.](image)

**Table 1.** Potency (EC50) and Efficacy (E_max) of compounds 3–6 on hA3AR.

| Compound | EC50 (μM) | E_max (%) |
|----------|-----------|-----------|
| 3        | Inactive  | N.A.      |
| 4        | 2.89 ± 0.55 | 31        |
| 5        | 13.4 ± 2.96  | 77        |
| 6        | 33.2 ± 16.50  | 72        |
| Adenosine| 0.35 ± 0.03  | 100       |

The TGFα shedding assay at hA2A AR was also performed on the compounds 3–6. Results (Figure 5) showed that compounds 3–6 are all essentially inactive against the human A2A AR, confirming that compounds 4–6 are all human A3AR-selective partial agonists with respect to the hA2A AR.
TGFα shedding assay results of compounds 3–6 on vector-transfected HEK293 cells, with neither human A2AAR nor human A3AR expressed (as shown in Figure 6) confirmed that the activity observed in the TGFα shedding assay on hA3AR-expressing HEK293 cells is due to the action of the compounds on the hA3AR, eliminating eventual external interferences in the HEK293 cells.

The shifting of carbonyl group position in the mIPP scaffold has led to significant reduction of the hA2AAR activity, while simultaneously increasing the hA3AR activity and selectivity as A3-selective partial agonists. Of note, previous studies had shown that hA3AR-selective full agonists could cause rapid desensitization via β-arrestin2 trafficking of the hA3AR upon receptor activation [23,24]. Consistently, Bar-Yehuda et al. reported that a reduction in the hA3AR expression level was observed in A3 full agonist-treated hepatocellular carcinoma (HCC) tumour-bearing rats as compared to vehicle-treated HCC tumour-bearing rats, indicative of desensitization and reduced expression of hA3AR [25]. In a study by Gao et al., the partial hA3AR-selective agonist, MRS541, was demonstrated to have a lower β-arrestin translocation response of 30.8 ± 1.6% in comparison to the full A3AR-selective agonists, IB-MECA and 2-Cl-IB-MECA, which have a high β-arrestin translocation response of 100 ± 7% and 102 ± 13%, respectively [26]. It can be deduced from these findings that hA3AR-selective partial
agonists would have a lower tendency of triggering rapid receptor trafficking and desensitization of hA3AR, particularly in cancers that overexpress the A3 receptors.

Among the four compounds, compound 4 was subsequently chosen for further evaluation of its anti-proliferative activity in human colorectal and liver cancer cell lines. This is because it is the most potent among the new mIPP derivatives, with an EC50 of 2.89 ± 0.55 μM at the hA3AR.

2.2.2. Cytotoxicity Assays of Compound 4 against Human Colorectal Cancer Cell Lines, a Normal Colon Cell Line and a Liver Cancer Cell Line.

Human colorectal carcinoma cell lines, HCT-116 and Caco-2, were used as models for colorectal cancer cells overexpressing hA3AR. Human normal colon cell line CCD-18Co was used as a model for normal colon cells that express normal levels of hA3AR. The HCT-116, Caco-2 and CCD-18Co cell lines were all cultured in accordance with the ATCC protocols.

Cytotoxicity assay results, as shown in Figure 7, indicated that compound 4 is approximately two times more cytotoxic towards the colorectal cancer cell lines, i.e., the HCT-116 cell line (IC50 = 84 ± 9 μM) and the Caco-2 cell line (IC50 = 77 ± 10 μM), than the normal colon cell line, the CCD-18Co cell line (IC50 = 176 ± 48 μM). Hence, compound 4 is cytotoxic-selective for the colorectal cancer cells over its normal counterpart.

![Figure 7. Concentration-effect curves of compound 4 against HCT-116, Caco-2 and CCD-18Co cell lines.](image)

As both healthy and cancerous livers have high expression of hA3AR, which is remarkably higher than that of colorectal cancer cells, human hepatocellular carcinoma cells (HepG2) were used to test if compound 4 is more potent against hepatocellular carcinoma cells versus human colorectal carcinoma cells. The HepG2 cell line was also cultured in accordance with the ATCC protocol.

Based on the results obtained, compound 4 showed higher cytotoxicity against the HepG2 cell line (IC50 = 30 ± 7 μM) (Table 2), a hepatocellular carcinoma cell line, than against the colorectal cancer cell lines. It also exhibited cytotoxicity of the same order of magnitude to 2-Cl-IB-MECA (Figure 8), a highly potent hA3AR-selective agonist. This result suggests that compound 4, a hA3AR-selective partial agonist, can exert the same cytotoxicity as the hA3AR-selective full agonist, 2-Cl-IB-MECA. This is probably due to the rapid hA3AR desensitization upon exposure of the cancer cell lines to the hA3AR full agonist, 2-Cl-IB-MECA, as a previous study by Fishman et al. showed significant downregulation of hA3AR protein level after only 18 h of IB-MECA treatment on PC-3 prostate carcinoma cells [27]. Compound 4 might have a lower tendency of causing hA3AR desensitization, which would account for the similar order of magnitude of cytotoxicity as 2-Cl-IB-MECA against the cancer cell lines. However,
this would need to be further confirmed with a biological study on compound 4 to assess its effect towards A3AR trafficking by β-arrestin.

Table 2. Cytotoxicity assay results of compound 4 and 2-Cl-IB-MECA against HCT-116, Caco-2 and HepG2.

|                | IC₅₀ (µM) |
|----------------|-----------|
| HCT-116        | 84 ± 9    |
| Caco-2         | 77 ± 10   |
| HepG2          | 30 ± 7    |

2.3. UV-Vis Stability Study of Compound 4

UV-vis stability study of compound 4 showed that it exhibited excellent stability in water, Roswell Park Memorial Institute (RPMI)-1640 culture medium and Dulbecco’s Modified Eagle’s medium (DMEM) culture medium over 72 h, as indicated by the absence of isosbestic points within the UV-vis spectrum (supplementary information).

2.4. Induced-Fit Docking of Compound 1 and Compounds 3–6 in hA3AR Homology Model

Induced-fit docking of compound 1 and compounds 3–6 was conducted to rationalize the hA3AR agonistic activity of compounds 3–6 based on the hA3AR homology model built from the active state hA2AAR crystal structure.

As observed in Figure 9A, the induced-fit docking pose for compound 1 indicated a distinct pose compared to that of compounds 4–6. We observed the absence of a crucial hydrogen bonding interaction between the carbonyl group of the amide and Asn250⁶.⁵⁵ of the hA3AR homology model in compound 1; conversely, the induced-fit docking pose for compound 4 showed the hydrogen bonding interaction between the carbonyl group adjacent to the indole ring and the Asn250⁶.⁵⁵. This docking result supports our postulation that the shift in position of the carbonyl group from the amide to the position adjacent to the indole ring would confer binding affinity for the hA3AR, which has been then proven by the gain of hA3 activity in compound 4.

Generally, the induced-fit docking poses for compounds 3–6 well overlapped with each other in the active site of the hA3AR homology model (shown in Figure 9B), adopting similar conformations with the formation of crucial hydrogen bonding interaction between the carbonyl group of the compounds and Asn250⁶.⁵⁵ as well as the π-π stacking interaction between the indolyl ring of the compounds and Phe168.
In particular, an interesting observation was made from the induced-fit docking results of compounds 3–6. The Trp2436.48 was found to adopt a different degree of rotation for compounds 4–6 as compared to that of compound 3 (shown in Figure 9C). Previous molecular modelling studies with a hA3AR homology model built from the hA2A AR crystal structure also reported similar observation of rotation of the Trp2436.48 residue from its inactive “vertical” conformation to the active “horizontal” conformation upon agonist binding [28–31]. In fact, a site-directed mutagenesis study reported in Gao et al. demonstrated that Trp2436.48 is a residue crucial for the A3 receptor activation [32–34]. This residue might act as a switch in TM6-mediated structural transition from the resting to the active state of the A3 receptor upon binding of agonist. The difference in rotation of Trp243 residue observed between compound 3 and compounds 4–6 is in concordance with our findings from the TGFα shedding assay, whereby compound 3 was found to be inactive against hA3AR, while compounds 4–6 showed relatively higher hA3AR agonistic activity.

![Figure 9](image-url)

**Figure 9.** (A) Overlapping docking poses of compound 1 (yellow) and compound 4 (green) in the hA3AR homology model. (B) Overlapping docking poses of compounds 3–6 in the hA3AR homology model. (C) Rotation of Trp2436.48 observed in induced-fit docking of 4, 5 and 6 (grey), absent in 3 (blue).

### 3. Materials and Methods

#### 3.1. Chemistry

General 1H and 13C nuclear magnetic resonance (NMR) spectra (DMSO-d6) were recorded on a Bruker DPX Ultrashield NMR (400 MHz). Chemical shifts are reported as parts per million (δ) relative to the solvent peak. Coupling constants (J) are reported in hertz (Hz). High Performance Liquid Chromatography (HPLC) analysis was conducted with Agilent HP-1100 system equipped with a diode array detector (DAD). Reactions were checked with thin layer chromatography (TLC) (Merck precoated 60F254 plates). Flash chromatography was performed on silica gel 60 (70-230 mesh, Merck). Unless otherwise stated, materials were obtained from commercial suppliers and used without further purification. All anhydrous and technical-grade solvents were also obtained from commercial suppliers and used without further purification or drying.

**2-Chloro-1-(1H-indol-3-yl)ethanone (7):** Pyridine (1 equiv.) was added to a solution of indole (1 equiv.) in 20 mL of dry dichloromethane under argon and the mixture was warmed to 60 °C. Chloroacetyl chloride (1 equiv.) was added dropwise over 10 min and the reaction mixture was allowed to stir at 60 °C for 1 h. The reaction mixture was poured into 40 mL of iced water and extracted with 40 mL of ethyl acetate (EA) twice. The organic layer was washed with brine before drying with anhydrous sodium sulphate. The mixture was concentrated in vacuo and crudes were dry-loaded onto silica gel and purified with column chromatography (EA: Hexane = 1:100 to 1:4) to give the desired product, 3-chloroacetylindole as a brownish solid in 50% yield. 1H NMR (400 MHz, DMSO-d6): δ = 12.12 (s, 1 H), 8.43 (d, 1 H, 8.43 J = 3.24 Hz, 1 H), 8.17–8.15 (m, 1 H), 7.51–7.49 (m, 1 H), 7.27–7.23 (m, 1 H), 7.23–7.20 (m, 1 H), 4.87 (s, 2 H). 13C NMR (DMSO-d6): δ = 186.16, 136.61, 134.75, 125.39, 123.19, 122.15, 121.15, 113.61, 112.33, 46.38.
4,6-Dimethyl-2-(piperazin-1-yl)pyrimidine (8): To a stirred solution of piperazine (5 equiv.) and potassium carbonate (5 equiv.) in 24 mL of deionized water, 2-chloro-4,6-dimethylpyrimidine (1 equiv.) in 6 mL of tetrahydrofuran was added. The reaction mixture was stirred at room temperature for 24 h. After 24 h, tetrahydrofuran was evaporated in vacuo and the aqueous layer was extracted with 25 mL of EA three times. The combined organic layer was dried with anhydrous sodium sulphate and dry-loaded onto silica gel. Crudes dry-loaded on silica gel were purified by flash chromatography (EA: Hexane = 1:100–100:1) to give 4,6-dimethyl-2-(piperazin-1-yl)pyrimidine as a white solid in 96% yield.

$^1$H NMR (400 MHz, DMSO-d$_6$): $\delta = 6.35$ (s, 1 H), 3.63 (t, $J = 5.00$ Hz, 4 H), 2.69 (t, $J = 4.88$ Hz, 4 H), 2.20 (s, 6H). $^{13}$C NMR (DMSO-d$_6$): $\delta = 166.47$, 161.28, 108.37, 45.55, 44.46, 23.69.

General procedure for direct acylation to obtain 7-methoxy and 7-chloro substituted 3-chloroacetylindole (9–10). 7-substituted indoles (1 equiv.) was weighed in a microwave vial and the microwave vial was capped after adding the stir bar before purging with argon. 5 mL of dichloroethane (DCE) was added to the microwave vial to dissolve the 7-substituted indoles. DBU (1 equiv.) was added to the reaction mixture and heated in an oil bath to 90°C. Upon reaching 90°C, chloroacetyl chloride (1.1 equiv.) was added in a single portion into the microwave vial via syringe. The reaction was stirred and monitored with TLC hourly until product spot was observed and qualitative yield was obtained, before heating was stopped. The reaction mixture upon cooling was added to a water-methanol mixture of 6:1 under vigorous stirring to quench the reaction. The quenched reaction was allowed to stir for an additional 1 h and solid crude product was filtered with a sintered glass filter funnel before washing with water. The crude product was allowed to dry in an oven before dissolving in methanol. The dissolved crude product was dry loaded onto silica gel and was purified with column chromatography (EA: Hexane = 1:100–1:4) to give the pure 7-substituted 3-chloroacetylindole.

2-Chloro-1-(7-methoxy-1H-indol-3-yl)ethanone (9): Brownish solid, yield: 23%. $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta = 12.27$ (s, 1 H), 8.32 (d, $J = 3.28$ Hz, 1 H), 7.74–7.72 (d, $J = 7.92$ Hz, 1 H), 7.14 (t, $J = 7.92$ Hz, 1 H), 6.82 (d, $J = 7.44$ Hz, 1 H), 4.88 (s, 2 H), 3.94 (s, 3H). $^{13}$C NMR (DMSO-d$_6$): $\delta = 186.20$, 146.27, 133.96, 126.94, 126.59, 122.95, 114.10, 113.64, 103.86, 55.32, 46.48.

2-Chloro-1-(7-chloro-1H-indol-3-yl)ethanone (10): Yellowish solid, yield: 11%. $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta = 12.50$ (s, 1 H), 8.52–8.51 (d, $J = 3.24$ Hz, 1 H), 8.13–8.11 (d, $J = 7.88$ Hz, 1 H), 7.36–7.33 (dd, $J = 7.64$ Hz, 0.68 Hz, 1 H), 7.23 (t, $J = 7.80$ Hz, 1 H), 4.94 (s, 2 H). $^{13}$C NMR (DMSO-d$_6$): $\delta = 186.42$, 135.55, 133.52, 127.27, 132.29, 122.79, 122.09, 116.62, 114.43, 46.54.

Procedure for Vilsmeier-Haack acylation to obtain 7-nitro substituted 3-chloroacetylindole (12). Chloroacetyl chloride (3 equiv.) was added dropwise to a stirring mixture of dimethylamine hydrochloride (1 equiv.) and triethylamine (1.1 equiv.) in an ice bath. The reaction was allowed to stir further in the ice bath for 3 h before 40 mL of water was added for quenching the reaction. The aqueous layer was extracted with 50 mL of dichloromethane (DCM) twice and the combined organic layer was washed three times with 50 mL of 1M hydrochloric acid. The organic layer was concentrated in vacuo before being dispersed in diethyl ether and stirred overnight. Solid precipitate was filtered away and the organic layer was reconcentrated in vacuo to afford the purified 2-chloro-N,N-dimethylacetamide (11) as a liquid.

7-nitroindole (1 equiv.) was dissolved in a neat solution of 11 (5 equiv.). The mixture was stirred under argon in an ice bath. Phosphorus oxychloride (2 equiv.) was added dropwise into the reaction mixture in the ice bath. The reaction mixture was allowed to stir overnight at room temperature. The reaction was neutralized with 4 mL of 2M aqueous sodium hydroxide solution. The aqueous layer was extracted with 10 mL of EA three times. Combined organic layers were washed with 30 mL saturated sodium bicarbonate twice. The organic layer was dried over anhydrous sodium sulphate and concentrated in vacuo. Residue obtained was purified with column chromatography (EA: Hexane = 1:100–1:4) to give pure 2-chloro-1-(7-nitro-1H-indol-3-yl)ethanone (12).
2-Chloro-N,N-dimethylacetamide (11): Dark brownish liquid, yield: 62%. 1H NMR (400 MHz, CDCl3): δ = 3.86 (s, 1 H), 2.81 (s, 3 H), 2.67 (s, 3 H). 13C NMR (CDCl3): δ = 166.06, 40.84, 36.92, 35.31.

2-Chloro-1-(7-nitro-1H-indol-3-yl)ethanone (12): Brownish solid, yield: 17%. 1H NMR (400 MHz, DMSO-d6): δ = 12.73 (s, 1 H), 8.64–8.62 (dd, J = 7.84 Hz, 0.92 Hz, 1 H), 8.57 (d, J = 2.08 Hz, 1 H), 8.24–8.21 (dd, J = 8.04 Hz, 0.90 Hz, 1 H), 7.47 (t, J = 7.96 Hz, 1 H), 5.02 (s, 2 H). 13C NMR (DMSO-d6): δ = 186.91, 137.11, 133.39, 129.35, 129.08, 128.82, 122.20, 120.18, 114.26, 46.80.

General procedure for synthesis of mIPP and its derivatives (3–6). Chloroacetylindole (1 equiv.) was added to a stirred mixture of 4,6-dimethyl-2-(piperazin-1-yl)pyrimidine (1 equiv.), potassium carbonate (3 equiv.) and sodium iodide (1 equiv.) in 60 mL of acetonitrile. The reaction mixture was stirred under reflux for 4 h. Upon completion of the reaction determined by TLC analysis, the reaction mixture was cooled to room temperature and acetonitrile was removed in vacuo to give a dry residue. The dry residue was washed with water to remove the salts and the precipitate was dissolved in methanol and dry-loaded onto silica gel. Crude dry-loaded on silica gel were purified by column chromatography (EA: Hexane = 1:100–3:1) to give mIPP and its derivatives.

2-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl)-1-(7-methoxy-1H-indol-3-yl)ethanone (4)

HPLC analysis of compound purity by two solvent systems: ACN:H2O = 70:30 (95%), MeOH:H2O = 70:30 (99%).

2-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl)-1-(7-nitro-1H-indol-3-yl)ethanone (6)

HPLC analysis of compound purity by two solvent systems: ACN:H2O = 70:30 (99%). Purification by prep-HPLC was conducted to obtain just the desired product (98% purity).

2-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl)-1-(7-chloro-1H-indol-3-yl)ethanone (5)

HPLC analysis of compound purity by two solvent systems: ACN:H2O = 70:30 (89%). Purification by prep-HPLC was conducted to obtain just the desired product (98% purity).

2-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl)-1-(1H-indol-3-yl)ethanone (3)

HPLC analysis of compound purity by two solvent systems: ACN:H2O = 70:30 (95%), MeOH:H2O = 70:30 (95%).

3.2. Biological Evaluation

3.2.1. TGFα Shedding Assays for hA2AAR and hA3AR

Expression vectors (250 ng of AP-TGFα plasmid, 100 ng of hA2AAR/hA3AR plasmid and 50 ng of Gα protein) were transfected into HEK293 cells using Lipofectamine 2000 (1.25 µL/well) in 12-well plates. Transfection of siRNA (final concentration: 10 nM) was conducted with Lipofectamine RNAiMAX
(1 µL/well), 48 h before assay to prevent interference from other signaling pathways. Transfected cells were detached with brief treatment with phosphate-buffered saline (PBS) containing 0.05% trypsin and 0.52 mM ethylenediaminetetraacetic acid (EDTA). The cell suspension was pelleted via centrifugation (190 g, 5 min). Trypsin was removed from the cells via resuspension in PBS, followed by 5 min of incubation at room temperature. Cells were subsequently pelleted with centrifugation (190 g, 5 min) and resuspended in Hank’s Balanced Salt Solution (HBSS) containing 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.4). Resuspended cells were plated in 90 µL/well in 96-well plate and incubated at 37 °C in 5% CO2 for 30 min. 10 µL of 10X concentration of compounds were added and incubated for 1 h at 37 °C in 5% CO2. Plates were centrifuged at 190 g for 2 min. 160 µL per well of conditioned medium (10 mM p-NPP, 40 mM Tris-HCl (pH 9.5), 40 mM NaCl & 10 mM MgCl2) was transferred into a conditioned medium plate and 80 µL per well of conditioned medium was added to the test compound plate. Absorbance at 405 nm (OD405) of both plates was read before and after a 1-h incubation at 37 °C using a microplate reader [22].

3.2.2. Cytotoxicity Assays

The cytotoxicity of compound 4 was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were harvested from culture flasks by trypsinisation and seeded into 96-well microculture plates (Costar, Corning, USA) at the seeding density of 6000 cells per well or 10,000 per well (CCD18Co). After the cells were allowed to resume exponential growth for 24 h, they were exposed to compound 4 or 2-Cl-IB-MECA in media for 72 h. The drugs were diluted in complete medium at the desired concentration, and 100 µL of the drug solution was added to each well and serially diluted to other wells. After exposure for 72 h, drug solutions were replaced with 100 µL of MTT in complete media (5 mg ml⁻¹) and incubated for an additional 1 h. Subsequently, the medium was aspirated and the purple formazan crystals formed in viable cells were dissolved in 100 µL of dimethyl sulfoxide (DMSO) per well. Optical densities were measured at 570 nm with a microplate reader. The quantity of viable cells was expressed in terms of treated/control (T/C) values by comparison to untreated control cells, and 50% inhibitory concentrations (IC50) were calculated from concentration-effect curves by interpolation using GraphPad Prism (Version 5.0, GraphPad Software, USA). Evaluation was based on means from at least three independent experiments, each comprising six replicates per concentration level.

3.3. UV-Vis Stability Assay

Stock solution of 50 µM of compound 4 was prepared in DMSO. Two quartz cuvettes were soaked in 70% ethanol in water for 1 h. The quartz cuvettes were subsequently left to dry in a biological safety cabinet. When both quartz cuvettes were dry, the quartz cuvettes, i.e., sample cuvette and blank cuvette, were filled with water or culture media (RPMI-1640 or DMEM) and parafilmmed before being transferred into a UV-vis spectrophotometer (USA). The UV-vis spectrophotometer was auto-zeroed and the background was scanned from wavelengths of 200 nm to 800 nm. The sample cuvette was removed from the UV-vis spectrophotometer and transferred into the biological safety cabinet. Compound 4 was dissolved at a final concentration of 50 µM in 1.5 mL of water, RPMI or DMEM containing 10% FBS (without phenol red). The UV–vis profiles of the samples were monitored using UV-vis over 72 h at 1 h intervals from 200 to 800 nm.

3.4. Molecular Modeling

3.4.1. Homology Modelling and Protein Preparation

The amino acid sequence of hA3AR was obtained from the UniProt Knowledgebase (P0DMS8) and was aligned to hA2AAR using the structural alignment specified in GPCRdb [35]. The N-terminal and C-terminal were truncated (residues 1-8 and 305-318). The hA3AR homology model was then constructed using Prime [36], based on the crystal structure of the active-state hA2AAR bound to the
selective agonist UK-432,097 as a template (PDB ID: 3QAK) [37]. The disulphide bridge between Cys83 and Cys166 in hA3AR was conserved. The stereochemical quality of the hA3AR homology model was assessed using PROCHECK [38] (supplementary information). The homology model was subsequently prepared for docking by assigning appropriate protonation states, which were generated at pH 7.4, and by optimizing the hydrogen bond networks. The resulting structure was subjected to energy minimization by using the OPLS 2005 force field.

3.4.2. Ligand Docking Studies

In-depth computational studies were conducted with Schrödinger Maestro using induced-fit docking protocol. Ligands were prepared for docking via LigPrep [39]. Ligand protonation states were generated at pH 7.4 using Epik [40]. The docking was then performed using the Induced Fit Docking protocol, with the docking grid centred on the hA3AR active site [41].

4. Conclusions

The present work confirmed our postulation that the structural modification of the IPP scaffold through shifting of the carbonyl group to the position adjacent to the indole ring would diminish the A2A activity while gaining activity at the A3 receptor. Among these newly synthesized mIPP derivatives, compound 4 was shown as a hA3AR-selective partial agonist with an EC$_{50}$ of 2.89 ± 0.55 µM and E$_{max}$ of 30% that exhibited some extent of selectivity for cancer cells over normal cells. Furthermore, the molecular modelling studies suggest that the difference in rotation of Trp243 residue might account for dissimilarity in agonistic activity observed among the new mIPP derivatives, indicating its role in A3 receptor activation. Further structural optimizations of compound 4 would be deemed useful in developing more potent hA3AR-selective partial agonists in the future.

In addition, relevant biological studies can be conducted to determine if the hA3AR partial agonist possesses a reduced tendency of causing desensitization of the hA3AR in cancer cells and reduced non-selective actions towards normal liver tissues that are intrinsically expressing high levels of hA3AR.

Supplementary Materials: The following are available online, Figure S1: 1H NMR of Compound 3., Figure S2: 13C NMR of Compound 3., Figure S3: 1H NMR of Compound 4., Figure S4: 13C NMR of Compound 4., Figure S5: 1H NMR of Compound 5., Figure S6: 1H NMR of Compound 5., Figure S7: 1H NMR of Compound 6., Figure S8: 13C NMR of Compound 6., Figure S9: UV-stability of Compound 4 in water over 72h., Figure S10: UV-stability of Compound 4 in DMEM over 72h., Figure S11: UV-stability of Compound 4 in RPMI-1640 over 72h. Figure S12: Ramachandran plot for hA3AR homology model (PROCHECK analysis).

Author Contributions: Conceptualization: A.T., G.S., G.P.; data curation: A.T., M.V.B., C.L., D.R.H., K.-N.K., J.S.E.L., G.P.; formal analysis: A.T., M.V.B., C.L., G.V., D.R.H., K.-N.K., J.S.E.L., G.P.; funding acquisition: G.P.; investigation: A.T., J.S.E.L., S.L.C., S.F.; methodology: A.T., D.R.H., K.-N.K., Y.Z.C., G.P.; project administration: S.F., G.S., S.L.C., G.P.; resources: G.P., W.-Y.O.; supervision: J.S.E.L., S.L.C., D.R.H., K.-N.K., W.-Y.O., G.P.; validation: J.S.E.L., S.L.C., G.P.; visualization: A.T., J.S.E.L., G.P.; writing: A.T., G.P.

Funding: This work was supported by the Research Support (WBS: C-141-000-097-001).

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Stewart, B.W.; Wild, C.P. World Cancer Report 2014; WHO: Geneva, Switzerland, 2014.
2. Valery, P.C.; Laversanne, M.; Clark, P.J.; Petrick, J.L.; McGlynn, K.A.; Bray, F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018, 67, 600–611. [CrossRef] [PubMed]
3. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
4. Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017, 66, 683–691. [CrossRef]
5. Sakowicz-Burkiewicz, M.; Kitowska, A.; Grden, M.; Maciejewska, I.; Szutowicz, A.; Pawelczyk, T. Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines. *Arch. Biochem. Biophys.* 2013, 533, 47–54. [CrossRef] [PubMed]

6. Stemmer, S.M.; Shani, A.; Klein, B.; Silverman, M.H.; Lorber, I.; Farbstein, M.; Shmueli, E.; Figer, A. A phase II, multi-center study of a new non-cytotoxic A3 adenosine receptor agonist CF101, dose-finding (randomized blinded) in patients with refractory metastatic colorectal cancer. *J. Clin. Oncol.* 2004, 22 (Suppl. 14), 3153. [CrossRef]

7. Bar-Yehuda, S.; Madi, L.; Silberman, D.; Gery, S.; Shkapenuk, M.; Fishman, P. CF101, An Agonist to the A3 Adenosine Receptor, Enhances the Chemotherapeutic Effect of 5-Fluorouracil in a Colon Carcinoma Murine Model. *Neoplasia* 2005, 7, 85–90. [CrossRef] [PubMed]

8. Borea, P.A.; Varani, K.; Vincenzi, F.; Baraldi, P.G.; Tabrizi, M.A.; Merighi, S.; Gessi, S. The A1 Adenosine Receptor: History and Perspectives. *Pharmacol. Rev.* 2015, 67, 74–102. [CrossRef] [PubMed]

9. Gessi, S.; Cattabriga, E.; Avitabile, A.; Gafa, R.; Lanza, G.; Cavazzini, L.; Bianchi, N.; Gambari, R.; Feo, C.; Liboni, A.; et al. Elevated Expression of A3 Adenosine Receptors in Human Colorectal Cancer Is Reflected in Peripheral Blood Cells. *Clin. Cancer Res.* 2004, 10, 5895–5901. [CrossRef]

10. Madi, L.; Ochaion, A.; Rath-Wolfson, L.; Bar-Yehuda, S.; Ohana, G.; Harish, A.; Merimski, O.; Barer, F.; Fishman, P. The A3 Adenosine Receptor is Highly Expressed in Tumor versus Normal Cells. Potential Target for Tumor Growth Inhibition. *Clin. Cancer Res.* 2004, 10, 4472–4479. [CrossRef]

11. Panjehpour, M.; Hemati, S.; Forghani, M.A. Expression of A1 and A3 Adenosine Receptors in Human Breast Tumors. *Tumori* J. 2012, 98, 137–141. [CrossRef]

12. Trincavelli, M.L.; Tuscano, D.; Marroni, M.; Falleni, A.; Gremigni, V.; Cerutti, S.; Abbracchio, M.P.; Jacobson, K.A.; Cattabeni, F.; Martini, C. A3 Adenosine Receptors in Human Astrocytoma Cells: Agonist-Mediated Desensitization, Internalization, and Down-Regulation. *Mol. Pharmacol.* 2002, 62, 1373–1384. [CrossRef] [PubMed]

13. Kohno, Y.; Sei, Y.; Koshiba, M.; Kim, H.O.; Jacobson, K.A. Induction of Apoptosis in HL-60 Human Promyelocytic Leukemia Cells by Adenosine A3 Receptor Agonists. *Biochem. Biophys. Res. Commun.* 1996, 219, 904–910. [CrossRef] [PubMed]

14. Llovet, J.; Zucman-Rossi, J.; Pikarsky, E. Hepatocellular carcinoma [serial online]. *Nat. Rev. Dis. Primers* 2016, 2, 16018. [CrossRef] [PubMed]

15. Stemmer, S.M.; Benjaminov, O.; Medalia, G.; Ciurarul, N.B.; Silverman, M.H.; Bar-Yehuda, S.; Fishman, S.; Harpaz, Z.; Farbstein, M.; Cohen, S.; et al. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study. *Oncologist* 2013, 18, 25–26. [CrossRef] [PubMed]

16. Shao, Y.-M.; Ma, X.; Paire, P.; Tan, A.; Herr, D.R.; Lim, K.L.; Ng, C.H.; Venkatesan, G.; Klotz, K.N.; Federico, S.; et al. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson’s disease treatment. *PloS ONE* 2018, 13, e0188212. [CrossRef]

17. Thompson, M.J.; Louth, J.C.; Ferrara, S.; Sorrell, F.J.; Irving, B.J.; Cochrane, E.J.; Meijer, A.J.; Chen, B. Structure–Activity Relationship Refined and Further Assessment of Indole-3-glyoxylamides as a Lead Series against Prion Disease. *ChemMedChem* 2011, 6, 115–130. [CrossRef]

18. Johansson, H.; Urruticochea, A.; Larsen, I.; Sejer Pedersen, D. A Scalable Method for Regioselective 3-Acylation of 2-Substituted Indoles under Basic Conditions. *J. Org. Chem.* 2015, 80, 471–481. [CrossRef]

19. Gitt, R.; De Luca, I.; Ferro, S.; Russo, E.; De Sarro, G.; Chisari, M.; Ciranna, L.; Alvarez-Builla, J.; Alajarin, R.; Buemi, M.R.; et al. Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors. *Mol. Pharmacol.* 2014, 22, 1040–1048. [CrossRef]

20. Wang, B.-L.; Shi, Y.-X.; Zhang, S.-J.; Ma, Y.; Wang, H.-X.; Zhang, L.-Y.; Wei, W.; Liu, X.H.; Li, Y.H.; Li, Z.M.; et al. Syntheses, biological activities and SAR studies of novel carboxamide compounds containing piperazinyl and arylsulfonyl moieties. *Eur. J. Med. Chem.* 2016, 117, 167–178. [CrossRef]

21. Gilbert, E.J.; Greenlee, W.J.; Miller, M.W.; Scott, J.D.; Stamford, A.W.; Inventors; USA. Assignee. Substituted Piperazines as CB1 Antagonists and Their Preparation. U.S. Patent US20130072468A1, 21 March 2013.

22. Inoue, A.; Ishiguro, J.; Kitamura, H.; Arima, N.; Okutani, M.; Shuto, A.; Higashiyama, S.; Ohwada, T.; Arai, H.; Makide, K.; et al. TGFβ shedding assay: An accurate and versatile method for detecting GPCR activation. *Nat. Methods* 2012, 9, 1021. [CrossRef]

23. Park, K.-S.; Hoffmann, C.; Kim, H.O.; Padgett, W.L.; Daly, J.W.; Brambilla, R.; Motta, C.; Abbracchio, M.P.; Jacobson, K.A. Activation and desensitization of rat A3-adenosine receptors by selective adenosine derivatives and xanthine-7-ribosides. *Drug Dev. Res.* 1998, 44, 97–105. [CrossRef]
24. Storme, J.; Canneta, A.; Van Craenenbroeck, K.; Stove, C.P. Molecular dissection of the human A3 adenosine receptor coupling with β-arrestin2. Biochem. Pharmacol. 2018, 148, 298–307. [CrossRef] [PubMed]
25. Bar-Yehuda, S.; Stemmer, S.M.; Madi, L.; Castel, D.; Ochaion, A.; Cohen, S.; Barer, F.; Zabutti, A.; Perez-Liz, G.; Del Valle, L.; et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-κB signal transduction pathways. Int. J. Oncol. 2008, 33, 287–295. [PubMed]
26. Gao, Z.-G.; Jacobson, K.A. Translocation of arrestin induced by human A3 adenosine receptor ligands in an engineered cell line: Comparison with G protein-dependent pathways. Pharmacol. Res. 2008, 57, 303–311. [CrossRef] [PubMed]
27. Fishman, P.; Bar-Yehuda, S.; Ardon, E.; Rath-Wolfson, L.; Barer, F.; Ochaion, A.; Madi, L. Targeting the A3 adenosine receptor for cancer therapy: Inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res. 2003, 23, 2077–2084. [PubMed]
28. Kim, S.-K.; Riley, L.; Abrol, R.; Jacobson, K.A.; Goddard, W.A., III. Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor. Proteins 2011, 79, 1879–1897. [CrossRef] [PubMed]
29. Ciancetta, A.; Jacobson, K.A. Structural Probing and Molecular Modeling of the A3 Adenosine Receptor: A Focus on Agonist Binding. Molecules 2017, 22, 449. [CrossRef]
30. Dal Ben, D.; Buccioni, M.; Lambertucci, C.; Marucci, G.; Thomas, A.; Volpini, R.; Cristalli, G. Molecular modeling study on potent and selective adenosine A3 receptor agonists. Bioorg. Med. Chem. 2010, 18, 7923–7930. [CrossRef]
31. Tosh, D.K.; Ciancetta, A.; Warnick, E.; O’Connor, R.; Chen, Z.; Gizewski, E.; Crane, S.; Gao, Z.G.; Auchampach, J.A.; Salvemini, D.; et al. Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists. J. Med. Chem. 2004, 47, 2077–2084. [PubMed]
32. Gao, Z.-G.; Kim, S.-K.; Biadatti, T.; Chen, W.; Lee, K.; Barak, D.; Kim, S.G.; Johnson, C.R.; Jacobson, K.A. Structural Determinants of A3 Adenosine Receptor Activation: Nucleoside Ligands at the Agonist/Antagonist Boundary. J. Med. Chem. 2002, 45, 4471–4484. [CrossRef]
33. Gao, Z.-G.; Chen, A.; Barak, D.; Kim, S.-K.; Müller, C.E.; Jacobson, K.A. Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor. J. Biol. Chem. 2002, 277, 19056–19063. [CrossRef] [PubMed]
34. Jacobson, K.A.; Kim, H.S.; Ravi, G.; Kim, S.-K.; Lee, K.; Chen, A.; Chen, W.; Kim, S.; Barak, D.; Liang, B.T. Engineering of A3 adenosine and P2Y nucleotide receptors and their ligands. Drug Dev. Res. 2003, 58, 330–339. [CrossRef]
35. Pandy-Szekeres, G.; Munk, C.; Tsonkov, T.M.; Mordalski, S.; Harpsoe, K.; Hauser, A.S.; Bojarski, A.J.; Gloriam, D.E. GPCRdb in 2018: Adding GPCR structure models and ligands. Nucleic Acids Res. 2018, 46, D440–D446. [CrossRef] [PubMed]
36. Jacobson, M.P.; Pincus, D.L.; Rapp, C.S.; Day, T.J.F.; Honig, B.; Shaw, D.E.; Friesner, R.A. A hierarchical approach to all-atom protein loop prediction. Proteins 2004, 55, 351–367. [CrossRef] [PubMed]
37. Yu, J.; Zhao, L.X.; Park, J.; Lee, H.W.; Sahu, P.K.; Cui, M.; Moss, S.M.; Hammes, E.; Warnick, E.; Gao, Z.G.; et al. N6-Substituted 5’-N-Methylcarbamoyl-4’-selenoadenosines as Potent and Selective A3 Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase Orientation. J. Med. Chem. 2017, 60, 3422–3437. [CrossRef] [PubMed]
38. Laskowski, R.A.; MacArthur, M.W.; Moss, D.S.; Thornton, J.M. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283–291. [CrossRef]
39. Schrödinger Release 2018-3: LigPrep; Schrödinger, LLC: New York, NY, USA, 2018.
40. Schrödinger Release 2018-3: Epik; Schrödinger, LLC: New York, NY, USA, 2018.
41. Schrödinger Release 2018-3: Schrödinger Suite 2018-3 Induced Fit Docking Protocol; Glide, Schrödinger, LLC: New York, NY, USA, 2016; Prime, Schrödinger, LLC: New York, NY, USA, 2018.

Sample Availability: Not available.